Latest Depression News

TrivarX has launched a pivotal mental health clinical trial in partnership with the US Department of Veterans Affairs, leveraging its innovative ECG-based technology to screen for major depressive episodes. The company also secured $2.25 million in funding, positioning it for regulatory milestones ahead.

Little Green Pharma reported a robust 40% revenue increase for FY25, driven by strong European sales and the strategic acquisition of Health House. The company also advanced clinical research and secured new therapy funding, positioning itself for continued growth.

Fin Resources Limited reported subdued exploration activity in Q1 2025 amid weak lithium prices but secured $445,000 via convertible notes and outlined plans for McKenzie Springs exploration.

Actinogen Medical advances its XanaMIA phase 2b/3 Alzheimer’s trial with faster patient enrolment and expands clinical sites, while achieving a pivotal FDA meeting outcome for its depression program. The company maintains a strong cash position, supporting ongoing development and commercialization efforts.

Tryptamine Therapeutics has secured a landmark agreement with Swinburne University to initiate the first clinical trial of its IV-infused psilocin formulation TRP-8803 for Binge Eating Disorder, aiming to build on promising Phase 2a data.

Emyria Limited reports sustained clinical success in its PTSD program, launches a new treatment-resistant depression therapy, and opens a second Empax Centre to meet growing demand. The company is progressing funding discussions with health insurers and government bodies to support expansion.

Somerset Minerals Ltd has raised $2.39 million to fund its maiden drilling and surface sampling campaign at the Coppermine copper-silver project in Nunavut, targeting high-grade mineralisation supported by strong geophysical and historical data.

ARB Corporation Limited posted a 5.9% rise in sales revenue to $361.7 million for 1H FY2025, driven by strong export growth, while profit before tax edged down 0.7% amid rising costs and subdued domestic vehicle sales.

BlueScope Steel reported a resilient $309 million underlying EBIT for 1H FY2025 despite depressed steel spreads, announcing a 30 cents per share interim dividend and extending its buy-back program. The company is targeting a $500 million incremental EBIT uplift by 2030 through cost initiatives and strategic growth projects.

BlueScope reported a $179 million net profit for 1H FY2025 amid challenging steel market conditions, while announcing a 30 cents per share dividend and a $240 million buy-back plan. The company is banking on cost initiatives and market recovery to boost earnings in the second half.

Amotiv Limited’s interim results reveal a 34.3% decline in net profit despite a 2.3% revenue increase, driven by significant impairments and restructuring costs. The company declared a fully franked interim dividend of 18.5 cents per share.

Actinogen Medical has published a peer-reviewed article confirming the efficacy of a 10 mg daily dose of Xanamem for treating neurological conditions, reinforcing its ongoing clinical trials in Alzheimer's and depression.